( )

CONMED Corporation (NASDAQ: CNMD), a medical technology company

specializing in medical devices for surgical and patient monitoring

markets, announced today that the Company will participate in the

Wells Fargo Securities 2012 Healthcare Conference on Wednesday, June

20, 2012 at 12:40 PM Eastern time, at the InterContinental Hotel in


Mr. Joseph J. Corasanti, President and Chief Executive Officer of

CONMED, will discuss the Company's business. The live webcast of

CONMED's presentation will be available at

in the Investors' section of the website and will be available for

replay through June 29, 2012.

CONMED Profile

CONMED is a medical technology company with an emphasis on surgical

devices and equipment for minimally invasive procedures and patient

monitoring. The Company's products serve the clinical areas of sports

medicine-arthroscopy, powered surgical instruments, electrosurgery,

cardiac monitoring disposables, endosurgery and endoscopic

technologies. Surgeons and physicians in a variety of specialties

including orthopedics, general surgery, gynecology, neurosurgery, and

gastroenterology use the Company's medical devices. Headquartered in

Utica, New York, the Company's 3,400 employees distribute its products

worldwide from several manufacturing locations.

Forward-Looking Information

Certain statements made in the presentation may constitute

forward-looking statements. The forward-looking statements are made

pursuant to the safe harbor provisions of the Private Securities

Litigation Reform Act of 1995 and relate to the Company's performance

on a going-forward basis. They will be based upon management's

expectations and involve risks and uncertainties which could cause

actual results, performance or trends, to differ materially from those

expressed in the forward-looking statements therein or in previous

disclosures. The Company believes that all forward-looking statements

made by it have a reasonable basis, but there can be no assurance that

management's expectations, beliefs or projections as expressed in the

forward-looking statements will actually occur or prove to be correct.

In addition to general industry and economic conditions, factors that

could cause actual results to differ materially from those discussed

in the forward-looking statements include, but are not limited to: (i)

the failure of any one or more of management's assumptions to prove to

be correct; (ii) the risks relating to forward-looking statements

discussed in the Company's filings with the Securities and Exchange

Commission, including the Company's Annual Report on Form 10-K for the

fiscal year ended December 31, 2011 and Quarterly Reports on Form

10-Q; (iii) cyclical purchasing patterns from customers, end-users and

dealers; (iv) timely release of new products, and acceptance of such

new products by the market; (v) the introduction of new products by

competitors and other competitive responses; (vi) the possibility that

any new acquisition (and its integration) or other transaction may

require the Company to reconsider its financial assumptions and

goals/targets; (vii) increasing costs for raw material,

transportation, or litigation; (viii) the risk of a lack of allograft

tissues due to reduced donations of such tissues or due to tissues not

meeting the appropriate high standards for screening and/or processing

of such tissues; and/or (ix) the Company's ability to devise and

execute strategies to respond to market conditions.